USPTO serial 88777346
CHIMERIC VIGOR
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- RIRIE, VERNA BETH
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CHIMERIC VIGOR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Camille M. Miller
Camille M. Miller COZEN O'CONNOR1650 MARKET STREETSUITE 2800PHILADELPHIA, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, placental tissue for use in scientific, laboratory and medical research; bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; human amniotic membrane and human chorionic membrane for use in scientific, laboratory and medical research; human collagen and extracellular matrix compositions for use in scientific, laboratory and medical research; biological preparations for use in scientific, laboratory and medical research; biological products for use in scientific, laboratory and medical research, namely, placental-derived natural killer cells | ACTIVE | — |
| 005 | Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, umbilical cord cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological preparations for medical use, namely, for the treatment of cancer and other diseases, namely, auto-immune diseases, inflammatory diseases, Crohn's Disease and Multiple Myeloma; biological products for medical use, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen; cells and biological tissue intended for hair restoration, namely, cells and biological preparations derived from blood, stem cells, umbilical cords, umbilical cord blood, and placental tissue; biological tissue intended for use as a wound covering; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical use, namely, placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen | ACTIVE | — |
| 042 | Research, development and testing services for others in the fields of genomics, biotechnology and pharmaceuticals; stem cell research services; research, development and testing services in the fields of genomics, biotechnology and pharmaceuticals, namely, collection, testing, processing, preservation, storage and retrieval of cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, and placental tissue; providing website featuring information in the field of medical research relating to banking stem cells and cord blood banking; medical research to find methods to restore the structure and function of damaged or diseased tissues and organs, including wound care, reconstructive medicine, whole organ and tissue regeneration and renewal; medical research regarding emergent cell therapies; medical research regarding allogeneic immunotherapy; providing on-line information, news and commentary in the field of medical research relating to the foregoing | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Celularity Inc.
- Other trademarks owned by Celularity, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named CHIMERIC VIGOR
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 28, 2023 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 28, 2023 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 30, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 29, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Dec 27, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Dec 27, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 29, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 27, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 27, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 27, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 1, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 30, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 30, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 30, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 28, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 8, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 16, 2021 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Jun 29, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 25, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 25, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 25, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 31, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 29, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 29, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 29, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 8, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 8, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 8, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 28, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 2, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 2, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 13, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 29, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 28, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 27, 2020 | ALIE | ASSIGNED TO LIE | — |
| Apr 27, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 27, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 27, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 17, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 4, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 1, 2020 | NWAP | NEW APPLICATION ENTERED | — |